Functional Genomics of C190T Single Nucleotide Polymorphism in Human N-Acetyltransferase 2

Abstract Nacetyltransferase 2 (NAT2) catalyzes Nacetylation and Oacetylation of many drugs and environmental carcinogens. Genetic polymorphisms in the NAT2 gene have been associated with differential susceptibility to cancers and drug toxicity from these compounds. Single nucleotide polymorphisms (SNPs) have been identified in the human NAT2 coding region. A new allele, NAT2*19, possessing the C190T (R64W) exchange, was recently identified. In order to understand the effect of this new SNP, recombinant NAT2*4 (reference) and NAT2*19 were expressed in yeast (Schizosaccharomyces pombe). The C190T (R64W) SNP in NAT2*19 caused substantial reduction in the NAT2 protein level and stability, but did not cause significant reduction in transformation efficiency or mRNA level. The enzymatic activities for Nacetylation of two arylamine carcinogens (2-aminofluorene, 4-aminobiphenyl), and a sulfonamide drug (sulfamethazine) were over 100-fold lower for NAT2 19 compared to reference NAT2 4. Kinetic studies showed a reduction in Vmax but no significant change in substrate Km. In addition, the SNP caused significant reduction in the Oacetylation of the Nhydroxy 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine. These results show that NAT2*19 possessing the C190T (R64W) SNP encodes a slow acetylator phenotype for both N and Oacetylation, due to a reduction in the amount and stability of the NAT2 19 allozyme.

[1]  Y. Pang,et al.  Theoretical 3D model of histamine N-methyltransferase: insights into the effects of a genetic polymorphism on enzymatic activity and thermal stability. , 2001, Biochemical and biophysical research communications.

[2]  M. Doll,et al.  Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. , 2001, Pharmacogenetics.

[3]  M. Doll,et al.  Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. , 2001, Pharmacogenetics.

[4]  E. Sim,et al.  Arylamine N-acetyltransferases - of mice, men and microorganisms. , 2001, Trends in pharmacological sciences.

[5]  M. Noble,et al.  Structure of arylamine N-acetyltransferase reveals a catalytic triad , 2000, Nature Structural Biology.

[6]  D. Grant,et al.  Update on consensus arylamine N-acetyltransferase gene nomenclature. , 2000, Pharmacogenetics.

[7]  K. Tokunaga,et al.  Novel allele containing a 190C>T nonsynonymous substitution in the N‐acetyltransferase (NAT2) gene , 2000, Human mutation.

[8]  M. Doll,et al.  Novel Human N-Acetyltransferase 2 Alleles That Differ in Mechanism for Slow Acetylator Phenotype* , 1999, The Journal of Biological Chemistry.

[9]  T. Rustan,et al.  Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  C. J. Omiecinski,et al.  Post-transcriptional regulation of human microsomal epoxide hydrolase. , 1998, Pharmacogenetics.

[11]  R. Minchin,et al.  Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. , 1998, Pharmacogenetics.

[12]  W. Evans,et al.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Rustan,et al.  Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. , 1994, Human molecular genetics.

[14]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Deguchi,et al.  Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. , 1990, The Journal of biological chemistry.

[16]  D. Grant,et al.  Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. , 1990, The Journal of clinical investigation.

[17]  W. Weber,et al.  N-acetylation pharmacogenetics. , 1985, Pharmacological reviews.

[18]  G. Church,et al.  Genomic sequencing. , 1993, Methods in molecular biology.

[19]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  W. Weber.  The acetylator genes and drug response , 1987 .